Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Have confirmed (stage IIIb-IV) or recurrent non-small cell lung cancer, adenocarcinoma histology

• Understand and voluntarily sign an informed consent document prior to any study related assessments or procedures are conducted

• Anticipated that they will complete all study procedures

• Ability to swallow pills

• No aspirin in the last 7 days

Exclusion Criteria:

• Know allergy to aspirin or other nonsteroidal anti-inflammatory drugs

• History of allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs, including ibuprofen

• Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety